CompletedNCT05414058
Methylphenidate added to treatment for schizophrenia-related thinking difficulties
About this title
Read the official source — NCT05414058Medication studyAges 18–55Canada
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- OttawaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 9, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 35
- Sponsor
- The Royal Ottawa Mental Health Centre
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT05414058
- Official title
Show the full official title
Adjunctive Methylphenidate Extended Release in Patients With Schizophrenia: a Single-centre Fixed Dose Cross-over Open-label Trial to Improve Functional and Cognitive Outcomes
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ottawa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is The Royal Ottawa Mental Health Centre.
Did this study involve medication?
Yes. The study involved medication, including Apo-Methylphenidate ER.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
